If a powerful CYP3A inhibitor is discontinued, increase abemaciclib dose (just after three-five 50 %-life with the inhibitor) into the dose which was applied before beginning the potent inhibitor Abemaciclib targets CDK4 and CDK6, proteins that help regulate mobile division. Cancer cells typicall